A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-05-31

Study Completion Date

2009-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the maximum tolerated dose (MTD) of E7974 after bolus IV administration, on Day 1 of a 21-day cycle, to patients with advanced solid tumors that have progressed following effective therapy or for which no effective therapy exists.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies

NCT00130169

Cancer, Malignant Tumors

COMPLETED PHASE1

An Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid Malignancies

NCT00121732

Solid Tumor Malignancies, Cancer

COMPLETED PHASE1

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors

NCT00794781

Advanced Solid Tumors

COMPLETED PHASE1

A Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors

NCT00869895

Cancer

COMPLETED PHASE1

Study of E7386 in Participants With Selected Advanced Neoplasms

NCT03264664

Advanced Neoplasms

ACTIVE_NOT_RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The MTD for the Day 1 21-Day schedule was defined at the 0.45 mg/m2 dose level. The study was terminated prior to full enrollment of the colorectal cancer (CRC) expansion cohort, due to a lack of demonstrated activity resulting in Principal Investigator (PI) loss interest to continue enrollment. Collection of all outstanding data is ongoing and database lock is estimated to be complete in June 2008.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer, Malignant Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

E7974

Intervention Type DRUG

Maximum Tolerated Dose defined as 0.45 mg/m\^2 administered on Day 1 only of a 21-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

E7974

Maximum Tolerated Dose defined as 0.45 mg/m\^2 administered on Day 1 only of a 21-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Have a histologically or cytologically confirmed advanced solid tumor that has progressed following effective therapy or for which no effective therapy exists (including surgery or radiation therapy).
2. Be \>= 18 years of age.
3. Have an Eastern Cooperative Oncology Group (ECOG) status of 0, 1, or 2.
4. Have a life expectancy of \>= 3 months.
5. Have adequate renal function as evidenced by serum creatinine \<= 1.5 mg/dL or creatinine clearance \>= 40 mL/minute.
6. Have adequate bone marrow function as evidenced by absolute neutrophil count \>= 1,500/µL, hemoglobin of \>= 9 g/dL (may be transfused), and platelet count (not transfused) \>= 100,000/µL.
7. Have adequate liver function as evidenced by bilirubin \<= 1.5 x ULN and alanine transaminase (ALT) and aspartate transaminase (AST) \<= 3 times the upper limits of normal (ULN), unless related to liver involvement by tumor, in which case \<= 5.0 x ULN.
8. Give written informed consent.
9. Be willing and able to comply with the study protocol for the duration of the study.
10. Be willing to undergo blood draw and urine sampling for PK in Cycle 1.
11. Can have either measurable or non-measurable disease.
12. If a CRC patient is being treated at the MTD, they must have \<= 4 prior regimens in the metastatic setting.

Exclusion Criteria

1. Patients who have received chemotherapy within 3 weeks of E7974 treatment start; (six weeks for nitrosoureas).
2. Patients who have not recovered from any chemotherapy-related or other therapy-related toxicity to \< Grade 1 at study entry (excluding alopecia Grade 2).
3. Patients who have received radiotherapy \<= 3 weeks prior to study enrollment, (prior radiation therapy allowed to \<25% of the bone marrow), and who have not recovered from the toxic effects of the treatment prior to study enrollment (except for alopecia). Lesions that have been radiated cannot be included as sites of measurable disease unless clear tumor progression has been documented in these lesions since the end of radiation therapy.
4. Patients who have had major surgery without full recovery or major surgery within three weeks of E7974 treatment start.
5. Patients with primary brain tumors or metastasis at study entry must have them controlled for \> one month by previous treatment, including radiation therapy and /or corticosteroids.
6. Women who are pregnant or breastfeeding.
7. Women of childbearing potential with either a positive pregnancy test at screening or no pregnancy test.
8. Women of childbearing potential unless (1) surgically sterile or (2) physiologically postmenopausal for \> 12 months, or (3) using adequate measures (including barrier methods) of contraception.
9. Fertile men or their partners who are not willing to use contraception.
10. Patients who have a history of positive testing for Human Immunodeficiency Virus (HIV) and/or have active hepatitis B or active hepatitis C at study entry.
11. Patients with severe, uncontrolled intercurrent illness or infection.
12. Patients with medically uncontrolled cardiovascular illness defined as unstable angina or congestive heart failure (CHF), with \> symptomatic Grade II New York Heart Association (NYHA) Classification, or myocardial infarction (MI) within six months prior to study entry.
13. Patients who have received organ allografts requiring immunosuppressive therapy.
14. Patients who have received investigational drugs including immunotherapy, gene therapy, hormone therapy, biologic therapy, or chemotherapy within the three-week period prior to E7974 treatment start; patients must have recovered from any previous major therapy related toxicity (Grade 3 or 4) to \<= Grade 1 at study entry.
15. Patients with a current history of peripheral neuropathy \> CTC Grade 2 (e.g., diabetic or chemotherapy-induced neuropathy).
16. Patients with a history of uncontrolled seizures.
17. Patients with other significant diseases or disorders that, in the investigator's opinion, would exclude them from the study.
18. Patients with marked screening or baseline prolongation QT/QTc interval (QTc interval \> 470 mm) using the Fridericia method as the main method of QTc analysis.
19. Patients with allergy or hypersensitivity to hemiasterlin based product or analogue.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No